Coronavirus

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

An assessment of 21 pediatric cases leads France investigators to believe development is due to post-viral immunological reactions.

Mild symptoms may still present high risk for SARS-CoV-2 transmission.

A quick brief on today's top infectious disease news.

Due to health concerns, the US FDA is reissuing some EUAs to clarify which respirators are suited for decontamination and reuse.

SARS-CoV-2 arrived in Northern California through a complicated series of introductions internationally and between states.

Mary Schmidt, MD, discusses challenges in translating infectious disease advice to policy action.

Pinar Karaca-Mandic, PhD, explains new research showing how exponentional rates of hospitalizations were avoided in 4 shut-down states.

Jason Pogue, PharmD, BCPS, BCIDP, speaks about the state of publishing during the COVID-19 pandemic.

A brief on today's top ID news.

Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.

John Strotbeck, CEO of Boathouse Sports, discusses results of physical distancing measures at the firm's COVID-adapted factory.

My hope is that years from now, when we look back on the coronavirus disease 2019 (COVID-19) pandemic, it will have served a few purposes.

The only new drug approved for COVID-19 treatment has limited efficacy, but is still desperately needed to fight pandemic.

Adam Brufsky, MD, PhD, addresses the potential for changing dynamics in SARS-CoV-2.

An assessment observing 4 states under stay-at-home orders showed all avoided worsened outcomes of severe infection rates.

Clinicians and researchers have questioned the likelihood of assembling the quantity of data supplied by Surgisphere on hydroxychloroquine in such a short period of time.

A brief on the latest infectious disease headlines.

Matthew F. Pullen, MD, co-author of the recent hydroxychloroquine prophylaxis trial, shares the top clinical takeaways.

The test measures IL-6 to identify patients with COVID-19 at high risk of intubation.

About two-thirds of patients that reported loss of smell associated with viral infection actually had confirmed anosmia after objective olfactory testing.

Though most trace the coronavirus outbreak to China, a new analysis finds most of the cases in New York seem to have originated in Europe.

The trial consisted of non-hospitalized adults who indicated a high-risk or moderate-risk exposure to COVID-19 through the household or an occupational setting.

Why people may need to readjust their expectations around COVID-19 clinical data and drugs.

John Strotbeck, Olympian and CEO of Boathouse Sports, explains how and why the outerwear company pivoted to PPE production at the start of the COVID-19 pandemic.

A review of the latest infectious disease news.

An eventual COVID-19 vaccination should be prepared to face obstacles before distribution, so the groundwork for factual information dissemination should begin now.

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, provides a deep dive on the pharmacology and biochemistry of remdesivir.

While COVID-19 may have impacted flu-like illness reporting, the CDC estimates there were between 24,000-62,000 related deaths this year.

A study team investigated the ideal physical distance for avoiding SARS-CoV-2 transmission and assessed the use of eye protection and face coverings in preventing acquisition.